Background: Off-label dosing of direct oral anticoagulants (DOAC) as a treatment for non-
valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of …

Background: Practice-based investigations on direct oral anticoagulant (DOAC) treatment for
non-valvular atrial fibrillation (NVAF) have shown that off-label under-dosing is increasingly …

Background: The safety and effectiveness of factor-Xa (FXa) inhibitors for nonvalvular atrial
fibrillation (NVAF) remains inconclusive. We investigated the current dosing of rivaroxaban …

Introduction Per-label dosing of direct oral anticoagulants (DOACs) is important for the
prevention of stroke and systemic embolism among patients with non-valvular atrial …

Background Direct-acting oral anticoagulants (DOACs) are widely prescribed for stroke
prevention in patients with atrial fibrillation (AF). An important advantage of DOACs is that …

Dabigatran and rivaroxaban, direct oral anticoagulants (DOACs), affect coagulation tests,
and knowledge of their effects is important for therapeutic monitoring. Our aim was to …

Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …

Background Routine laboratory monitoring of rivaroxaban and dose adjustment relating to
exposure is currently not recommended. However, in certain clinical situations, assessment …

Background: Edoxaban is a once-daily (QD) oral, direct factor Xa inhibitor in clinical
development for the prevention of stroke in patients with non-valvular atrial fibrillation …

Background Rivaroxaban is a non‐vitamin K oral anticoagulant and has been approved for
prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation …